Cantor Fitzgerald Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Strong-Buy”

Zevra Therapeutics (NASDAQ:ZVRA) was upgraded by equities research analysts at Cantor Fitzgerald to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Several other brokerages have also issued reports on ZVRA. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Canaccord Genuity Group decreased their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, Guggenheim began coverage on shares of Zevra Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $20.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $21.57.

Zevra Therapeutics Trading Up 2.0 %

Shares of Zevra Therapeutics stock opened at $8.02 on Wednesday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm has a market cap of $428.08 million, a price-to-earnings ratio of -4.07 and a beta of 2.01. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The business has a 50-day moving average price of $8.56 and a 200-day moving average price of $7.92.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter in the prior year, the business posted ($0.40) EPS. Equities research analysts anticipate that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ZVRA. International Assets Investment Management LLC raised its position in shares of Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after acquiring an additional 5,940 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares in the last quarter. Hunter Associates Investment Management LLC acquired a new stake in shares of Zevra Therapeutics during the third quarter worth $92,000. XTX Topco Ltd purchased a new stake in Zevra Therapeutics during the 3rd quarter valued at about $94,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Zevra Therapeutics in the fourth quarter valued at approximately $94,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.